Join
Live feed
·
PRReleasevia Quantisnow
Advanced Biomed Inc. logo

Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery

ByQuantisnow·Wall Street's wire, on your screen.
ADVB· Advanced Biomed Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ADVB (Advanced Biomed Inc.) and more on Quantisnow.